-
1
Giant cell arteritis (GCA) is a medical emergency that can lead to vision loss, cerebrovascular events, and significant cardiovascular complications.
-
2
Current evidence on low-dose aspirin for GCA is limited to observational studies, leading major guidelines to discourage its routine use for primary cardiovascular prevention.
-
3
Beydon et al's study analyzed data from 15,206 GCA patients, finding low-dose aspirin associated with reduced major adverse cardiovascular events at 1 year.
-
4
Despite the ischemic benefits observed, low-dose aspirin also increased the risk of major hemorrhage, resulting in neutral net clinical benefits at 1 and 3 years.
-
5
The study highlights the need for cautious, individualized decision-making regarding low-dose aspirin use in GCA due to the absence of randomized clinical trial data.
